France’s new 10-year cancer strategy and its implications on the rare disease space

By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com On World Cancer Day, 4th February 2021, President Emmanuel Macron announced France’s 10-year Cancer plan1. His predecessors have rolled out these strategies before, but they have been mid-term 5-year strategies. France has taken on board previous cancer plan insights and built an ambitious holistic 10-year strategy now. The plan…

Will AIFA’s net price disclosure requirement be a game-changer for Orphan Drug access?

By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: akumar@partners4access.com abernardini@partners4access.com In the latest guidelines for Pricing and Reimbursement (P&R) dossier submissions, Italian Medicines Agency (AIFA) requires manufacturers to self-report prices, including the percentage discounts and/or Management Entry Agreements (MEAs) agreed with other EU countries and the UK. If these are confidential agreements, AIFA in…